Answers · Views and frameworks
OpenEvidence is valued at $15 billion. Why is an AI search engine for doctors worth so much?
FutureX's view: the first big winner in medical AI is not a new drug but the information entry point doctors use every day; whoever owns the clinical decision entry point gets the hardest distribution to copy. Accuracy evidence still needs independent testing, which is its biggest risk.
OpenEvidence is an AI question-answering tool for doctors that cites medical literature. In October 2026 the Financial Times reported its valuation at $15 billion. Its growth came from word of mouth among doctors, followed by institutional deals: Johns Hopkins Medicine uses it in medical education and clinical support, and in November Apple partnered with it on a health AI usage study covering 200,000 people.
Sources: Financial Times (2026-10-20) on the $15 billion valuation; Fierce Healthcare (2026-10-13) on the Johns Hopkins deal; Apple's newsroom, Healthcare Dive, MobiHealthNews (2026-11-16) and AI Insider (2026-11-17) on Apple's study opening 200,000 slots; MobiHealthNews (2026-10-28) on the American Society of Addiction Medicine partnership.
The risk is evidence. In October STAT noted that OpenEvidence's JAMA paper leaves open questions. In medicine, user growth is not clinical reliability; hospitals and regulators ultimately look at independent evaluation. We think the long-term value of this category depends on turning usage scale into verifiable accuracy data.
Source: STAT (2026-10-20) commentary on its JAMA paper. Note: FutureX does not hold OpenEvidence; for drug discovery see the Isomorphic Labs Q&A.
Report · Healthcare AI Now Prices on Revenue: OpenEvidence's Sales Doubled, Valuation Rose Only 25% →Q&A · Isomorphic Labs and AI Drug Discovery →
Related answers
FutureX core theses
All theses →Updated 2026-11-19. Facts and examples come from FutureX Capital's published research, public talks, and public reporting, graded per our site-wide standard (verified / reported / per company disclosure). Nothing here is investment advice or an offer.